Indian govt mulling PLI scheme for basic chemicals and API industries

8 June 2023

The Indian government is exploring the possibility of introducing a Production Linked Incentive (PLI) scheme for basic chemicals and active pharmaceutical ingredients (API) industries. The objective of the scheme is to promote domestic manufacturing, increase production, and reduce import dependency.

Minister of Health and Family Welfare and Chemicals and Fertilizers of India Mansukh Mandaviya said the government is developing a PLI scheme on the lines of the earlier PLI scheme for pharmaceuticals and bulk drugs, in order to harness the enormous potential in the pharmaceutical and chemicals sector.

The PLI for basic chemicals is aimed at making the country self-reliant and ensuring affordability in the agro-chemicals, petrochemicals, and pharmaceutical API industries, Mr Mandaviya stressed, adding that the need for research and development in the API field was paramount in order to keep the standards high to help maintain India's world-class reputation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK